183 related articles for article (PubMed ID: 15843546)
1. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
Rohrbach F; Weth R; Kursar M; Sloots A; Mittrücker HW; Wels WS
J Immunol; 2005 May; 174(9):5481-9. PubMed ID: 15843546
[TBL] [Abstract][Full Text] [Related]
2. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
Burkhardt UE; Sloots A; Jakobi V; Wei WZ; Cavallo F; Kloke BP; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1473-84. PubMed ID: 22331080
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
4. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
5. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.
Drew DR; Boyle JS; Lew AM; Lightowlers MW; Chaplin PJ; Strugnell RA
Vaccine; 2001 Aug; 19(31):4417-28. PubMed ID: 11483267
[TBL] [Abstract][Full Text] [Related]
6. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
7. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
J Immunol; 1997 May; 158(10):4584-90. PubMed ID: 9144470
[TBL] [Abstract][Full Text] [Related]
8. Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides.
Schirmbeck R; Fissolo N; Chaplin P; Reimann J
J Immunol; 2003 Aug; 171(3):1240-6. PubMed ID: 12874211
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
12. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen.
Huang TH; Wu PY; Lee CN; Huang HI; Hsieh SL; Kung J; Tao MH
Blood; 2000 Dec; 96(12):3663-70. PubMed ID: 11090045
[TBL] [Abstract][Full Text] [Related]
15. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
17. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
18. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
Mol Ther; 2008 Mar; 16(3):607-17. PubMed ID: 18180774
[TBL] [Abstract][Full Text] [Related]
19. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
[TBL] [Abstract][Full Text] [Related]
20. Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.
Lamolinara A; Stramucci L; Hysi A; Iezzi M; Marchini C; Mariotti M; Amici A; Curcio C
J Immunol Res; 2015; 2015():159145. PubMed ID: 26247038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
